Back to search

Article

Discovery of a novel pharmacogenomic biomarker on ANK3gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression

2025-06-02

Abstract excerpt

<title>Abstract</title> <p>Liafensine is a first-in-class triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine for treatment-resistant depression (TRD). It did not exhibit efficacy in non-biomarker-selected TRD patients in two Phase 2b studies. We utilized the blood samples from the patients enrolled in these two studies and extracted genomic DNA to conduct a genome‑wide as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c95f7fe7-4712-5584-8ff9-06cb7d9f65ac
DOI
10.21203/rs.3.rs-6736436/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discovery of a novel pharmacogenomic biomarker on ANK3gene for liafensine, a triple reuptake inhibitor for treatment-resistant depressionDOI 10.21203/rs.3.rs-6736436/v1
A randomized, double-blind, placebo-controlled phase 2b trial using the novel predictive genetic biomarker DGM4 for liafensine in treatment-resistant depressionSemantic proximity
Genomic predictors of response to antidepressants in Major depressive disorder (MDD): A GWAS-Based Study on Indian cohortSemantic proximity
Role of the Pharmacogenomics in the Treatment-Resistant Depression: A Literature ReviewSemantic proximity
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patientsSemantic proximity
The association of β-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients.Semantic proximity
The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.Semantic proximity
Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis.Semantic proximity
International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets.Semantic proximity
The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression.Semantic proximity
DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.Semantic proximity
The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response Study: Design and MethodologySemantic proximity
Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state.Semantic proximity
Select a neighboring publication to make it the new centre.